Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment

A new study published today in Nature Communications shows a promising alternative for those who have to take a daily pill regimen. Targeting HIV treatment and prevention, researchers across multiple departments at the University of North Carolina at Chapel Hill collaborated on a seven-year study in animals to make a better injectable drug implant that can combine multiple drugs and […]

Read more

Long-Acting Regimen Noninferior to Daily ART for HIV-1

MONDAY, March 11, 2019 — Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic Infections, held from March 4 to 7 in Seattle. Susan Swindells, M.B.B.S., from the University of Nebraska Medical Center in Omaha, and colleagues conducted a phase […]

Read more